A Vancouver-based company has identified six hours as the optimum peak stimulation period for neuron outgrowth by N,N-Dimethyltryptamine, more commonly known as DMT.
Story continues below
This advertisement has not loaded yet, but your article continues below.
The study is part of Algernon Pharmaceuticals Inc.’s clinical research program focused on DMT, the main psychoactive ingredient in ayahuasca, as a potential treatment option for stroke.
In September, the company established that DMT can increase the growth of cortical neurons by 40 per cent .
The in vitro study was conducted by Charles River Laboratories and aimed to optimize the neuroplastic effects of DMT at sub-psychedelic levels.
“These exciting in vitro data provide further evidence supporting the use of DMT in
Read full article on The Growth Op
